A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
The purpose of this study is to find the highest dose of durvalumab or of durvalumab with
tremelimumab that can be tolerated without causing very severe side effects when receiving
standard chemotherapy and to see what effects the study drugs has on this type of cancer.
Patients may receive durvalumab alone or in combination with tremelimumab.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society